Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.
“Current statistical models are too simple. They fail to capture complex biological variations across people, discarding them as mere noise. We suspected this could partly explain why so many drug trials work in simple animals but fail in the complex brains of humans. If so, machine learning capable of modelling the human brain in its full complexity may uncover treatment effects that would otherwise be missed,” said the study’s lead author, Dr Parashkev Nachev (UCL Institute of Neurology).
To test the concept, the research team looked at large-scale data from patients with stroke, extracting the complex anatomical pattern of brain damage caused by the stroke in each patient, creating in the process the largest collection of anatomically registered images of stroke ever assembled. As an index of the impact of stroke, they used gaze direction, objectively measured from the eyes as seen on head CT scans upon hospital admission, and from MRI scans typically done 1-3 days later.
They then simulated a large-scale meta-analysis of a set of hypothetical drugs, to see if treatment effects of different magnitudes that would have been missed by conventional statistical analysis could be identified with machine learning. For example, given a drug treatment that shrinks a brain lesion by 70%, they tested for a significant effect using conventional (low-dimensional) statistical tests as well as by using high-dimensional machine learning methods.
The machine learning technique took into account the presence or absence of damage across the entire brain, treating the stroke as a complex “fingerprint”, described by a multitude of variables.
“Stroke trials tend to use relatively few, crude variables, such as the size of the lesion, ignoring whether the lesion is centred on a critical area or at the edge of it. Our algorithm learned the entire pattern of damage across the brain instead, employing thousands of variables at high anatomical resolution. By illuminating the complex relationship between anatomy and clinical outcome, it enabled us to detect therapeutic effects with far greater sensitivity than conventional techniques,” explained the study’s first author, Tianbo Xu (UCL Institute of Neurology).
The advantage of the machine learning approach was particularly strong when looking at interventions that reduce the volume of the lesion itself. With conventional low-dimensional models, the intervention would need to shrink the lesion by 78.4% of its volume for the effect to be detected in a trial more often than not, while the high-dimensional model would more than likely detect an effect when the lesion was shrunk by only 55%.
“Conventional statistical models will miss an effect even if the drug typically reduces the size of the lesion by half, or more, simply because the complexity of the brain’s functional anatomy—when left unaccounted for—introduces so much individual variability in measured clinical outcomes. Yet saving 50% of the affected brain area is meaningful even if it doesn’t have a clear impact on behaviour. There’s no such thing as redundant brain,” said Dr Nachev.
The researchers say their findings demonstrate that machine learning could be invaluable to medical science, especially when the system under study—such as the brain—is highly complex.
“The real value of machine learning lies not so much in automating things we find easy to do naturally, but formalising very complex decisions. Machine learning can combine the intuitive flexibility of a clinician with the formality of the statistics that drive evidence-based medicine. Models that pull together 1000s of variables can still be rigorous and mathematically sound. We can now capture the complex relationship between anatomy and outcome with high precision,” said Dr Nachev.
“We hope that researchers and clinicians begin using our methods the next time they need to run a clinical trial,” said co-author Professor Geraint Rees (Dean, UCL Faculty of Life Sciences).
Learn more: Improving clinical trials with machine learning
The Latest on: Machine learning clinical trials
- Gut microbiome, big data and machine learning to promote precision medicine for canceron July 9, 2020 at 11:55 am
The ‘omics’ technologies used for microbiome analysis continuously evolve and, although much of the research is still at an early ... role and limitations of a machine learning-driven approach to ...
- Further Clinical Implementation of Deep Learning Segmentation in Treatment Planning System RayStation Takes Place at Leeds Cancer Centreon July 9, 2020 at 7:59 am
PRNewswire/ -- RaySearch Laboratories AB (publ) announces that its advanced deep learning segmentation functionality for lung delineation in breast ...
- WellAI Data Scientists to Present Latest Research on Machine Learning in Healthcare and Financeon July 9, 2020 at 7:00 am
WellAI data scientists Daniel Satchkov and Sergei Polevikov will present their most recent research entitled "Reading 25 Million Studies ...
- Innovative machine learning approaches used to create a comprehensive view of breast cancer risk factorson July 7, 2020 at 6:59 am
The machine learning model developed at the Institute of Clinical Medicine ... and machine learning at Mannermaa cancer research laboratory.
- Using machine learning to analyze the interaction of breast cancer risk factorson July 6, 2020 at 5:21 am
A recently published article from University of Eastern Finland and Kuopio University Hospital reports new innovative use of machine learning to help understand the interplay of genetic and other ...
- Side Effects of Testicular Cancer Predicted by Machine Learningon June 29, 2020 at 12:29 pm
"In testicular cancer patients, cisplatin-based chemotherapy is essential to ensure a high cure rate. Unfortunately, treatment can cause side effects, including renal impairment. However, we are not ...
- Machine Learning Network Determines Severity of Lung Canceron June 29, 2020 at 7:55 am
A machine learning tool analyzed CT scans to offer information about lung cancer severity and guide treatment options.
- Machine learning model predicts chemotherapy-associated nephrotoxicityon June 26, 2020 at 6:45 am
In collaboration with Rigshospitalet, researchers from DTU Health Technology have developed a machine learning model that can predict chemotherapy-associated nephrotoxicity, a particularly significant ...
- Dayzz Sleep App Announces Publication of the Findings From Clinical Trial to Validate Its Sleep Assessment Machine Learning Engineon June 25, 2020 at 6:27 am
Innovative sleep solution provider dayzz announced this week the results of its first clinical trial. dayzz' machine learning engine enables assessment of common sleep disturbances using a proprietary ...
- Scientists use machine learning to predict major clinical forms of drug cardiotoxicityon June 9, 2020 at 7:05 am
June 9, 2020 - We announce the publication of a new research paper titled 'Dual transcriptomic and molecular machine learning predicts all major clinical forms of drug cardiotoxicity' in Frontiers ...
via Google News and Bing News